Reichert's ClearChart 2 digital acuity system is LINUX-based and free of hard drives, fans, and other moving parts for silent and "lock-up-free" operation.

Safilo offers stylish back-to-school options by releasing 15 new children's frames in its Carerra Kids, Chesterfield, Nine West, and Juicy Girls eyewear collections.

An exchange-traded fund can offer an inexpensive way to diversify an investment portfolio.

Aton Pharma has acquired the U.S. marketing rights to the Timoptic (timolol maleate) product line from Merck & Co.

The George Washington University School of Public Health and Health Services study, "Assessing the Need for On-Site Eye Care Professionals in Community Health Centers," found that the absence of eye-care services in rural and low-income areas is a major public health crisis that puts individuals at greater risk for undiagnosed and untreated eye and vision problems.

Vistakon, Division of Johnson & Johnson Vision Care, and the American Optometric Foundation have announced the 2009 recipients of the Dr. Terrance Ingraham Pediatric Optometry Residency Awards, the Dr. George W. Mertz Contact Lens Residency Awards, and the Dr. Sheldon Wechsler Contact Lens Residency Awards.

With the enactment of the American Recovery and Reinvestment Act of 2009 (HR 1) in Denver, the National Alliance for Eye and Vision Research praised Congress and biomedical research champions that facilitated the $10 billion in funding for the National Institutes of Health.

Essilor of America has announced the winners of its enhanced Independent Distribution Division Advantage Plan Annual Laboratory Awards.

Prevent Blindness America recently launched the Healthy Eyes Vision Wellness Program to help businesses provide the tools employees need to protect their ocular health.

EMRlogic has announced that Scot Morris, OD, and Ben Gaddie, OD, will help shape enhanced capabilities for the company's OD Professional and MD Professional software solutions.

B vitamins may help prevent age-related macular degeneration in older women, according to The Women's Antioxidant and Folic Acid Cardiovascular Study, the first rigorous study of its kind, published in the Feb. 23 edition of Archives of Internal Medicine (2009;169:335-341).

Lux Biosciences began a phase 1 study of LX214, a proprietary topical ophthalmic solution containing the next-generation calcineurin inhibitor voclosporin.